Pane will be replaced by Alan Thompson, currently general manager of RB Canada, who will relocate to the UK in July and take responsibility for the UK business.
As global category officer for healthcare, Pane will be responsible for driving innovation, equity and growth in the category, which includes the Nurofen, Strepsils and Gaviscon brands.
RB says the healthcare division is the fastest growing part of the business and hopes Pane’s experience in the UK over the counter medicine (OTC) market will boost the global business.
Pane oversaw the acquisition and integration of SSL’s Durex and Scholl brands last year.
He will remain based in the UK at RB’s Slough head office.
Read Marketing Week’s profile of Camillo Pane here